PET/CT in the evaluation of the treatment response in lymphomas Lenfomalarda tedavi yanıtının değerlendirilmesinde PET/BT

Mütevelizade G. Y.

Nuclear Medicine Seminars, vol.7, no.2, pp.177-186, 2021 (Scopus) identifier

  • Publication Type: Article / Review
  • Volume: 7 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.4274/nts.galenos.2021.0017
  • Journal Name: Nuclear Medicine Seminars
  • Journal Indexes: Scopus, EMBASE
  • Page Numbers: pp.177-186
  • Keywords: F-18 FDG PET/CT, Lymphoma, Treatment response
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

The Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is a functional and metabolic imaging modality with high sensitivity and accuracy for staging, restaging, and evaluation of response to treatment in Non-Hodgkin and Hodgkin lymphoma patients. Objective and accurate evaluation of treatment response in interim (iPET) and end of treatment (ePET) PET/CT is one of the most important parameters of patient management. In this review, standardization studies used in the evaluation of treatment response with PET/CT in lymphomas, the importance of iPET and ePET in patient management, metabolic tumor markers and pitfalls that can be followed in PET/CT after treatment were evaluated.